No Data
No Data
Novavax Stock Rises as Revenue Beat Estimates
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax Posts Q4 Revenue Beat Despite 80% Drop in Product Sales
FDA AdCom Meeting on Flu Vaccines Canceled
Sanofi's Sustained Revenue Growth Potential: Buy Rating Justified by Extended Amvuttra Royalties
CDC A(H5N1) Bird Flu Response Update February 26, 2025; Confirmed 3 Human Cases Of H5 Bird Flu In People Who Became Ill In 2025 - Website